Merriman Curhan initiates coverage on Salix Pharmaceutical (Nasdaq: SLXP) with a Buy.

Merriman analyst says, "We believe Salix represents a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE